Parsaclisib (INCB050465) (Synonyms: INCB050465) |
カタログ番号GC32916 |
パルサクリシブ (INCB050465) (INCB050465) は、PI3Kδ の強力で選択的な経口活性阻害剤であり、1 mM ATP で 1 nM の IC50 を有します。パルサクリシブ (INCB050465) は、他の PI3K クラス I アイソフォームよりも約 20000 倍の選択性を示します。パルサクリシブ (INCB050465) は、再発または難治性の B 細胞性悪性腫瘍の研究に使用できます。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1426698-88-5
Sample solution is provided at 25 µL, 10mM.
Parsaclisib is a potent and selective PI3Kδ inhibitor, with an IC50 of 1 nM at 1 mM ATP, and shows appr 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ and 57 other kinases.
Parsaclisib (INCB050465) is a potent and selective PI3Kδ with an IC50 of 1 nM at 1 mM ATP, and shows appr 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ and 57 other kinases. Parsaclisib displays significant activity with IC50 values ranging from 0.2 to 2 nM in B and T cell proliferation aaasys. Parsaclisib inhibits proliferation of several DLBCL and MCL cell lines in vitro (EC50 < 10 nM)[1].
[1]. Niu Shin, et al. Abstract 2671: INCB050465, a novel PI3Kδ inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL. Cancer Research. 2015, Aug. 75(15).
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *